← Leaderboards
Horng H Chen
Mayo Clinic Rochester
$12,297,202
Attributed
$14,351,062
Total exposure
7
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,351,062 · 7
By mechanism
R01$10,526,744 · 3
P01$2,319,750 · 2
P20$1,453,109 · 1
M01$51,459 · 1
Top collaborators
- John C Burnett7 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Sasantha Jeson Sangaralingham$3,919,348
- Siobhan Malany$5,060,787
- Alessandro Cataliotti$966,441
- Yong-Mei Cha$1,983,474
- Yasuhiro Ikeda$1,841,468
Others in their field
Top investigators on “Kidney”
- Jeffrey P Krischer · University Of South Florida$540,222,210
- John M Lachin · George Washington University$155,894,464
- David M Nathan · Massachusetts Institute Of Technology$127,229,266
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$111,521,899
- David Heimbrook · Leidos Biomedical Research, Inc.$83,221,586
- Peter Scott Heeger · Case Western Reserve University$80,562,246
Research focus
KidneyNatriuretic PeptidesHeart FailureAcuteBrain Natriuretic PeptidePeptidesFundingPropertyVentricularRenal FunctionCardiacCyclic GmpClinicNovel TherapeuticsChronicPreventLeftFunctional DisorderReportingClinical ResearchHuman StudyPhysiologicalBaseMyocardial
Grant awards (32)
Human Cardiorenal Syndrome$397,102
R01 · FY2025 · HL · contact PI
Human Cardiorenal Syndrome$397,102
R01 · FY2024 · HL · contact PI
Human Cardiorenal Syndrome$397,102
R01 · FY2023 · HL · contact PI
Human Cardiorenal Syndrome$397,102
R01 · FY2022 · HL · contact PI
Preclinical Diastolic Dysfunction in Type 2 Diabetes$691,534
R01 · FY2021 · HL · contact PI
Preclinical Diastolic Dysfunction in Type 2 Diabetes$691,534
R01 · FY2020 · HL · contact PI
Preclinical Diastolic Dysfunction in Type 2 Diabetes$691,753
R01 · FY2019 · HL · contact PI
Human Cardiorenal Syndrome$388,669
R01 · FY2019 · HL · contact PI
Preclinical Diastolic Dysfunction in Type 2 Diabetes$693,343
R01 · FY2018 · HL · contact PI
Human Cardiorenal Syndrome$389,169
R01 · FY2018 · HL · contact PI
Human Cardiorenal Syndrome$389,641
R01 · FY2017 · HL · contact PI
Cardiovascular Peptides and Myocardial Infarction$539,884
R01 · FY2016 · HL
Human Cardiorenal Syndrome$390,085
R01 · FY2016 · HL · contact PI
Cardiovascular Peptides and Myocardial Infarction$531,785
R01 · FY2015 · HL
Cardiovascular Peptides and Myocardial Infarction$529,087
R01 · FY2014 · HL
Cardiovascular Peptides and Myocardial Infarction$513,971
R01 · FY2013 · HL
Human Cardiorenal Syndrome$337,193
R01 · FY2013 · HL · contact PI
Cardiovascular Peptides and Myocardial Infarction$539,884
R01 · FY2012 · HL
Human Cardiorenal Syndrome$354,920
R01 · FY2012 · HL · contact PI
Protein Therapeutics to Prevent Heart Failure Post Myocardial Infarction$702,819
P20 · FY2011 · HL
Maximizing the cGMP System in Preclinical Left Ventricular and Renal Dysfunction$494,451
P01 · FY2011 · HL · contact PI
Human Cardiorenal Syndrome$359,254
R01 · FY2011 · HL · contact PI
Protein Therapeutics to Prevent Heart Failure Post Myocardial Infarction$750,290
P20 · FY2010 · HL
Human Cardiorenal Syndrome$453,601
R01 · FY2010 · HL · contact PI
Human Cardiorenal Syndrome$453,029
R01 · FY2009 · HL · contact PI
Natriuretic Peptide System as Therapy in Human Preclinical LV Dysfunction$345,737
P01 · FY2009 · HL · contact PI
Natriuretic Peptide System as Therapy in Human Preclinical LV Dysfunction$379,411
P01 · FY2008 · HL · contact PI
Natriuretic Peptide System as Therapy in Human Preclinical LV Dysfunction$381,539
P01 · FY2007 · HL · contact PI
ANP as Therapy in Human Preclinical LV Dysfunction$361,715
P01 · FY2006 · HL · contact PI
ANP as Therapy in Human Preclinical LV Dysfunction$356,897
P01 · FY2005 · HL
CARDIAC HORMONE REPLACEMENT WITH SQ BNP: A NOVEL THERAPEUTIC STRATEGY$32,224
M01 · FY2005 · RR
Cardiac Hormone Replacement--BNP, Novel Therapy for CHF$19,235
M01 · FY2004 · RR